Current and emerging strategies in the management of venous thromboembolism: Benefit–risk assessment of dabigatran

Medicine & Life Sciences

• Dabigatran 100%
• Venous Thromboembolism 81%
• Anticoagulants 26%
• Vitamin K 21%
• Orthopedics 17%
• Fondaparinux 13%
• Antithrombins 11%
• Therapeutics 10%
• Low Molecular Weight Heparin 10%
• General Practice 9%
• Standard of Care 9%
• Heparin 8%
• Risk Assessment 7%
• Cause of Death 7%
• Clinical Trials 6%
• Morbidity 5%
• Drug Therapy 5%
• Recurrence 5%
• Mortality 4%
• Population 3%

Social Sciences

• management 36%
• Clinical Practice 34%
• drug therapy 27%
• Clinical Trials 19%
• morbidity 19%
• mortality 15%
• incident 15%
• monitoring 13%
• death 13%
• cause 11%
• interaction 8%